A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles.

"Disclosure Statement Sloan Kettering has filed for IP protection for inventions related to α particle technology of which M.R.M. and D.A.S. are inventors. M.R.M. was a consultant for Actinium Pharmaceuticals, Regeneron, Progenics, and General Electric. D.A.S. is a consultant to and has equity in Actinium Pharmaceuticals, Eureka Therapeutics, Pfizer, and Progenics Pharmaceuticals (also a Board member). D.A.S. has equity in IOVA. K.M., M.S.B., and U.W. disclose a financial interest in Elucida Technologies, Inc., which has licensed C dot IP from Cornell and MSKCC."

"Funding Information NIH U54 CA132378, NIH P30 CA008748, NIH R01 CA161280, NIH R01 CA55349, the Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, and The Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center."